Explore a new optical device that performs real-time, user-friendly, and label-free measurements of lentiviral vector physical titer and size distribution.

This study describes a “plug-and-play” setup for cell expansion in Corning CellCube 25-layer modules in the absence of a bioreactor controller.

Review our work to establish a protocol for culturing Vero cells in serum-free medium on the Corning CellCube System, a compact and scalable method for mass culture of attachment-dependent cells.

This study establishes basic cell culture parameters for expansion of DF-1 cells in the Corning CellCube System—a compact and scalable method for mass culture of attachment-dependent cells.

A biomanufacturing company has released the results of an internal study where they demonstrate comparability for a new manufacturing platform combining bioreactors and microcarriers using MSCs.

Researchers looking for reliable ways to recapitulate physiological conditions are turning to spheroids and other 3D objects, seeking ways to mass-produce 3D models for various applications.

Achieve a more physiologically relevant setting with less reliance on model animals when studying diseases like cancer through the combination of CRISPR screening and bulk spheroid production.

Scientists are working to discover new and effective ways precision medicine can prevent, diagnose, and treat diseases such as cancer.

Investigate important considerations for working with three different stem cell types: mesenchymal stem/stromal cells, induced pluripotent stem cells, and neural stem cells.

The cryopreservation process maintains the structural integrity of living cells, but what other information is crucial for manufacturers when considering cryopreservation and its impact on cell-based therapies?

During each Cell & Gene Live, our audience can submit real-time questions for our expert panelists. Watch and listen as Michael Blackton and John Lee provide detailed, insightful responses to our audience questions on everything from how changing from a lab-based adherent protocol to suspension scalable protocol improved the cell product to whether a container with lesser cells, identical cell density, and composition be used for establishing stability for cell therapy products, and much more.

During Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee provided detail on how successful comparability studies are designed and executed. They covered the in-process and release testing requirements, as well as the common and uncommon pit falls that have been encountered.

For cell-based products, donor-to-donor variability is the primary source of complexity associated with establishing product comparability. In this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee cover why donor-to-donor variability is an on-going challenge and potential solutions.

Here, during this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee highlight the various ways to demonstrate our understanding of how the process influences the product, as well as how the product’s structure influences its clinical function.

As a therapy proceeds through Phases I / II and into Phase III clinical trials, the comparability burden increases. As the body of knowledge increases, the comparability burden evolves. Some tests may be removed while others are added, and assumptions may change with data. In this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee break down the comparability requirements from early- to late-stage programs.

During this Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Cell & Gene's Chief Editor, Erin Harris, Michael Blackton, former SVP Cell Therapy Manufacturing at Nurix Therapeutics, and John Lee, SVP, Head of Cell Therapy at Center for Breakthrough Medicines, talk through the CGT sector's greatest struggles with comparability. Indeed in this segment, Blackton and Lee cover the sector's biggest challenges to date from the need to truly understand the product to precise analytics and eliminating silos, and more.

In this video our application scientists walk you through common research goals and the most suitable 3D cell culture solutions for each.

There are many harvesting options depending on the cell line and application. In this video we discuss some tips and tricks for harvesting cells.

The Corning® Matribot® bioprinter uses a revolutionary cooling syringe printhead technology that allows you to dispense 3D droplets or droplet arrays for organoid applications.

With gas-permeable film, this closed system offers more surface area within a compact footprint. Watch this short video to learn more.

We visit the MEARY Center to see how they produce new cells and new gene therapy drugs to treat patients suffering from autoimmune, hematological, and cardiac diseases, and so much more.

In the complex world of cell and gene therapy, having a seasoned partner to guide you through uncharted production territory is critical to success.

Corning’s Field Applications Specialists work with scientists like you to overcome complex manufacturing challenges and streamline the path to production.

The Ascent FBR System’s novel mesh substrate intensifies cell growth surface area to produce high cell yields more efficiently.

When you need a reliable path from research to bioprocessing try efficient tools like the Corning® HYPERFlask® cell culture vessel.